PrimeRFP SCOUT · Federal Contract Recompete Brief

19AQMM22F41482022-2023 fluarix and flulaval vaccine delivery — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 36F79722D0178. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Oct 6, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Acquisitions - Aqm Momentum

Awarding office

Glaxosmithkline LLC

Recipient

Oct 6, 2022

PoP end

$634K

Obligated

$778K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number19AQMM22F4148

Also listed as19AQMM-22-F-4148

Also listed as36F79722D0178-19AQMM22F4148

AgencyAcquisitions - Aqm Momentum

Awarding officeAcquisitions - Aqm Momentum

Awarding agencyDepartment of State (DOS)

Funding agencyDepartment of State (DOS)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79722D0178

Place of performanceSTERLING VA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startSep 23, 2022

PoP end (current)Oct 6, 2022

Obligated$634K

Current value$778K

Potential value$778K

2022-2023 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. FOR DOS ACCOUNT. is a federal award for Acquisitions - Aqm Momentum held by Glaxosmithkline LLC. Estimated value $778K ($634K obligated). Current period of performance ends Oct 6, 2022. Last award drew 1 bidder. Place of performance: STERLING VA.

2022-2023 FLUARIX AND FLULAVAL VACCINE DELIVERY ORDER. FOR DOS ACCOUNT.

Recompete timing

Public

● Past PoP end (1456 days ago)

Current PoP ended Oct 6, 2022 (1456 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 19AQMM22F4148? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

75A50124F61013

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …

$15.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 19AQMM22F4148?

19AQMM22F4148 (2022-2023 fluarix and flulaval vaccine delivery) is a Acquisitions - Aqm Momentum award with a potential value of $778K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 19AQMM-22-F-4148?

19AQMM-22-F-4148 is the dashed form of PIID 19AQMM22F4148 (2022-2023 fluarix and flulaval vaccine delivery), held by Glaxosmithkline LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 19AQMM22F4148?

Acquisitions - Aqm Momentum awarded 19AQMM22F4148 to Glaxosmithkline LLC (potential $778K).

Who is the incumbent on 19AQMM22F4148?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Oct 6, 2022.

When does Glaxosmithkline LLC’s 19AQMM22F4148 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 6, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 19AQMM22F4148? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jul 24, 2024